FERTAID
|
|
     
|
DISCPLINES: Embryology Andrology Ultrasound Endocrinology
Modules
 
Information on QA Scheme: Halosperm DNA EQA 2022
Comment = An EQA/Competency schemes for the assessment of sperm DNA fragmentation by the Halospem method. This has been expanded to 12 data sets from 2013 with images from several users. Participants are shown 20+ sets of images from one sample and asked to estimate the number Normal and abnormal sperm ( according to the methodology) and calculate a % DFI
Number of enrollments =61 [* This indicates only the number of enrollments. Not all participants will have completed the scheme]
List of QA Issues (or Instalments)
Code Title Available from
HAL2022.01 Halosperm January 2021 1/1/2022
HAL2022.02 Halosperm February 2021 1/2/2022
HAL2022.03 Halosperm March 2021 1/3/2022
HAL2022.04 Halosperm April 2021 1/4/2022
HAL2022.05 Halosperm May 2021 1/5/2022
HAL2022.06 Halosperm June 2021 1/6/2022
HAL2022.07 Halosperm July 2021 1/7/2022
HAL2022.08 Halosperm August 2021 1/8/2022
HAL2022.09 Halosperm September 2021 1/9/2022
HAL2022.10 Halosperm October 2021 1/10/2022
HAL2022.11 Halosperm November 2021 1/11/2022
HAL2022.12 Halosperm December 2022 1/12/2022
List of Questions asked for QA Scheme:Halosperm DNA EQA 2022
ID Question Question Format
636 % Grade A - No Halo [Highly Fragmentation/Abnormal] Numeric Outcome
637 % Grade B - small Halo [Moderate Fragmentation/Abnormal] Numeric Outcome
638 % Grade C - moderate halo [Mild Fragmentation/Normal] Numeric Outcome
639 % Grade D - Large Halo [No Fragmentation/Normal] Numeric Outcome
640 % Grade E - Degenerate Sperm (not counted in %DFI in 2012, included from 2013) Numeric Outcome
641 Is the %DFI clinically significant? Defined Options
635 What is the % DNA fragmentation by Halosperm [(A+B)/[A+B+C+D)] Numeric Outcome
Detailed Information on Question: % Grade A - No Halo [Highly Fragmentation/Abnormal]
Status This is not a key question for the Scheme    
Type Numeric Outcome
Order Question Options
2 % no Halo
 
© FertAid Pty Ltd. 2002 - all pages. All rights reserved.